Clin2
NCT05672108Possibly a fitRecruiting

Chemo delivered into lung tumors using a catheter

Lung Non-Small Cell CarcinomaMediastinal NeoplasmPleural NeoplasmLung Metastases From Any PrimaryEndobronchial MetastasesColon CancerSarcoma

Treatments studied

Part of Cancer, Digestive system, Lungs & breathing clinical trials.

This trial studies a treatment that delivers chemotherapy directly to lung tumors by placing a catheter into lung blood vessels. It may help people with lung cancer or lung metastases that are growing despite standard treatment, or who cannot tolerate it.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have lung cancer or lung metastases that are mainly in the chest and are growing despite standard treatment, or you cannot tolerate standard treatment
  • Your tumors cannot be removed with surgery, treated with heat/ablation, or treated with one-time focused radiation aimed at the tumor
  • Your breathing and lung function are adequate (oxygen level on room air is at least 92%, and FEV1 is at least 60%)
  • There is measurable tumor that can be followed on scans (for example, not only tiny nodules under 1 cm)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04267848Recruiting· Phase 3
Testing immunotherapy with chemo after lung cancer surgery

This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.

Anchorage, Alaska
NCT07738367Enrolling by invitation· Phase 2
Bronchial artery chemoembolization with drug therapy for advanced lung cancer

This trial tests a treatment called bronchial artery chemoembolization (BACE) combined with drug therapy for advanced non-small cell lung cancer. BACE delivers chemotherapy directly to the tumor through the blood vessel that feeds it, which may help control the cancer when standard treatments have stopped working.

Fuzhou, Fujian
NCT07567313Not yet recruiting· Phase 4
Lung cancer treatment with or without artery chemotherapy

This trial tests whether adding a special chemotherapy procedure (bronchial artery chemoembolization) to standard treatment improves outcomes for advanced lung squamous cell carcinoma patients who have already completed initial chemotherapy and immunotherapy. The procedure delivers cancer-fighting drugs directly to blood vessels feeding the tumor.

NCT06037733Recruiting
Focused radiation to main tumor after chemo-immunotherapy for lung cancer

This trial is for people with advanced non-small cell lung cancer whose tumors responded well to initial chemo-immunotherapy. Instead of giving full chest radiation, doctors will only target the main tumor to see if it can prevent regrowth with fewer side effects.

Wuhan, Hubei
NCT07333053Recruiting
Chemotherapy through a catheter for advanced colorectal cancer

This trial tests giving chemotherapy directly into the artery that feeds the tumor, which may help control advanced colorectal cancer that cannot be removed with surgery. It is for people who have not yet had other treatments and whose main tumor is in the colon or rectum.

Xicheng, Beijing Municipality
NCT06102057Recruiting· Phase 2
PET-guided small volume chemoradiation with immunotherapy for lung cancer

This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.

Dresden

Hear when a new Colon Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.